Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Single Arm, Open-label Trial of Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy

Next Previous
Search
Trial Profile

A Phase II, Single Arm, Open-label Trial of Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dalpiciclib (Primary) ; Fulvestrant (Primary) ; Pyrotinib (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 04 Jun 2024 Status changed from not yet recruiting to recruiting, according to Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 04 Jun 2024 Results (n=15) assessing efficacy and safety of dalpiciclib, fulvestrant, and pyrotinib in patients with HR-positive and HER2-low advanced breast cancer (BC), who have experienced disease progression after treatment with CDK4/6 inhibitors and aromatase inhibitors, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 12 Apr 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top